CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
16 hedge funds and large institutions have $1.06M invested in CASI Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 7 closing their positions.
11.02% less ownership
Funds ownership: 21.2% → 10.18% (-11%)
27% less funds holding
Funds holding: 22 → 16 (-6)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
75% less capital invested
Capital invested by funds: $4.33M → $1.06M (-$3.26M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$18.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$834 |
| 3 |
Morgan Stanley
New York
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMV
Foresite Capital Management VI
Larkspur,
California
|
-$1.63M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$304K |
| 3 |
WSCM
Wellington Shields Capital Management
New York
|
-$115K |
| 4 |
WSC
Wellington Shields & Co
New York
|
-$50K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$41.7K |
CASI Hedge Fund Activity: Q4 2025 in Review
16 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2025, worth a combined $1.06M — down 75% from $4.33M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CASI and 1 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $18.2K. The largest seller was Foresite Capital Management VI, exiting entirely with an estimated $1.63M sold.
- 16 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2025, down from 22 in Q3 2025.
- Funds reported $1.06M of CASI Pharmaceuticals stock for Q4 2025, down 75% quarter-over-quarter.
- 1 fund opened new CASI Pharmaceuticals positions in Q4 2025 and 7 closed out, a net change of -6 holders.
- The largest CASI Pharmaceuticals buyer in Q4 2025 was Citadel Advisors, an estimated $18.2K added.
- The largest CASI Pharmaceuticals seller in Q4 2025 was Foresite Capital Management VI, an estimated $1.63M sold.
Based on aggregated 13F filings for Q4 2025.